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KIR3DL2 belongs to the killer immunoglobulin (Ig)-like
receptors (KIRs) family and is composed of three extra-
cellular Ig-like domains. KIR3DL2 is naturally expressed
on some NK cells and minor subpopulations of CD8+
and CD4+ T cells. Physiologically, KIRD3L2 is an inhibi-
tory receptor for human leukocyte antigen (HLA) class I
molecules regulating NK cell activation. Remarkably,
KIR3DL2 is also aberrantly overexpressed on several sub-
types of T lymphomas/leukemias, such as Sezary Syn-
drome, transformed Mycosis Fungoides and HTLV1+
Adult T Cell Leukemia, making it a unique therapeutic
target in cancer. We have generated a series of anti-
KIR3DL2 monoclonal antibodies (mAbs) binding selec-
tively to KIR3DL2, spanning epitopes on all three Ig
domains. Their efficacy was evaluated in vitro and in vivo
against KIR3DL2-expressing tumors and Sezary cell lines
as disease model. An autologous assay was set up to eval-
uate the killing of primary Sezary cells by patients’ NK
effectors in the presence of those mAbs. Potent antibody-
dependent cell cytotoxicity (ADCC) was found the main
mode of action involved in their anti-tumor activity. The
most promising candidates were humanized as IgG1
mAbs and the final lead molecule was selected for further
development, based on several predefined criteria. In
parallel, anti-KIR3DL2 mAbs were also developed as
unique and sensitive tools for the detection by immuno-
histochemistry of KIR3DL2 on tumor biopsies. Owing to
the promising efficacy profile of our anti-KIR3DL2 mAb
candidate and to the highly restricted expression pattern
of the target on some T leukemia/lymphoma cells, an
antibody-based therapy targeting KIR3DL2 stands as a
potentially unequalled strategy in several orphan diseases
with critical unmet medical need.
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